Article
Trastuzumab deruxtecan in patients with solid tumours harbouring specific activating HER2 mutations (DESTINY-PanTumor01): an international, phase 2 study.
The Lancet. Oncology - 1 Jun 2024
Li Bob T, Meric-Bernstam Funda, Bardia Aditya, Naito Yoichi, Siena Salvatore, Aftimos Philippe, Anderson Ian, Curigliano Giuseppe, de Miguel Maria, Kalra Maitri, Oh Do-Youn, Park Joon Oh, Postel-Vinay Sophie, Rha Sun Young, Satoh Taroh, Spanggaard Iben, Michelini Flavia, Smith Ann, Machado Karime Kalil, Saura Cristina
Abstract excerpt
BACKGROUND: Trastuzumab deruxtecan is a HER2-directed antibody-drug conjugate approved by the US Food and Drug Administration and the European Medicines Agency for HER2-mutant non-small-cell lung cancer. Few treatment options exist for patients with HER2-mutant solid tumours beyond lung cancers. We investigated trastuzumab deruxtecan in metastatic solid tumours with specific activating HER2 mutations. METHODS: In...
Topics
Join the communities discussing this publication.